Last reviewed · How we verify
LY3832479
LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).
LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9). Used for Metastatic non-small cell lung cancer, Metastatic triple-negative breast cancer.
At a glance
| Generic name | LY3832479 |
|---|---|
| Also known as | LY-CoV016, Etesevimab |
| Sponsor | Eli Lilly and Company |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting CDK9, LY3832479 prevents the phosphorylation and activation of RNA polymerase II, leading to a decrease in messenger RNA (mRNA) synthesis and a subsequent reduction in protein production. This mechanism is thought to be beneficial in the treatment of various cancers.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic triple-negative breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (PHASE2, PHASE3)
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (PHASE2)
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (PHASE3)
- A Study of LY3832479 (LY-CoV016) in Healthy Participants (PHASE1)
- A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |